Phase 1Data readout

VTP-1000

Celiac disease

BRNSBarinthus Biotherapeutics plc [Formerly Vaccitech]

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: VTP-1000
Development stage: Phase 1
Event type: Data readout
Indication: Celiac disease

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for VTP-1000 in Celiac disease. The expected timing is based on the latest available company guidance and may change.

Development notes

AVALON trial. 9/24/24- Ph1 trial initiated. 11/7/25- SAD ongoing with data before YE 2025. MAD portion ongoing with data in H2 2026. 12/10/25:- SAD completed with dose-dependent pharmacological effect, no treatment-related SAEs. MAD gluten-challenge data expected H2 2026. 03/13/26:- SAD portion showed good tolerability and PD responses; MAD gluten-challenge data still expected H2 2026. 04/30/26:- MAD AVALON cohort progressing; gluten-challenge Phase 1 data still expected in H2 2026. 08/06/26:- AVALON MAD enrollment completed; topline data expected Q4 2026, SAD poster Oct 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source